Communiqués Medexus Pharmaceuticals Inc.

Actions

MDP

CA58410Q2036

Marché Fermé - Toronto S.E. Autres places de cotation 22:50:53 05/07/2024			Varia. 5j.	Varia. 1 janv.
2,21 ^CAD	+4,74 %		+21,43 %	-10,53 %

26/06	Transcript : Medexus Pharmaceuticals Inc., Q4 2024 Earnings Call, Jun 26, 2024
06/06	Medexus Pharmaceuticals Inc. annonce que la FDA accepte d'examiner la NDA du tréosulfan	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Medexus Pharmaceuticals : Management Discussion & Analysis FY 2024	26/06	PU
Medexus Pharmaceuticals : Financial Statements FY 2024	26/06	PU
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024	25/06	NE
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call	18/06	NE
Medexus Pharmaceuticals - FDA Accepts for Review Treosulfan NDA Resubmission	07/06	AQ
Canadian Investment Regulatory Organization Trading Halt - MDP	06/06	AQ
Canadian Investment Regulatory Organization Trade Resumption - MDP	06/06	AQ
FDA Accepts for Review Treosulfan NDA Resubmission	06/06	NE
Federal Court Finds Patent For Concentrated Methotrexate Solutions Obvious	07/05	AQ
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada	01/05	NE
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	02/04	NE
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients	27/03	AQ
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients	26/03	NE
Medexus Announces Fiscal Q3 2024 Results	07/02	NE
Medexus Schedules Third Fiscal Quarter 2024 Conference Call	30/01	NE
Medexus Pharmaceuticals - Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	09/01	AQ
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	08/01	NE
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million	08/11	NE
Medexus Schedules Second Fiscal Quarter 2024 Conference Call	01/11	NE
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering	17/10/23	NE

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Medexus Pharmaceuticals Inc.

Actions

MDP

CA58410Q2036

Communiqués

Filtres